Last reviewed · How we verify
BOL-303259-X
BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye.
BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye. Used for Geographic atrophy (age-related macular degeneration).
At a glance
| Generic name | BOL-303259-X |
|---|---|
| Also known as | latanoprostene bunod |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Complement C5 inhibitor |
| Target | Complement C5 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
The drug targets complement component C5, a key node in the complement cascade that drives inflammatory responses. By blocking C5 activation, it prevents the formation of the membrane attack complex and reduces recruitment of inflammatory cells to ocular tissues. This mechanism is intended to treat complement-mediated inflammatory and degenerative eye diseases.
Approved indications
- Geographic atrophy (age-related macular degeneration)
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Vision-related adverse events
Key clinical trials
- A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension (PHASE4)
- Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity (NA)
- Nailfold Capillary Blood Flow With Latanoprost Bunod (PHASE4)
- Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE2)
- Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT (PHASE3)
- Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOL-303259-X CI brief — competitive landscape report
- BOL-303259-X updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI